Edap Tms Sa ADR (FOCL) Stock Price, Quote & News

Company Profile

EDAP TMS S.A., doing business as FocalTherics, operates as a medical technology company that develops, manufactures, markets, and sells non-invasive therapeutic ultrasound and energy-based medical devices in Asia, France, the United States, and internationally. The company develops, manufactures, markets, and distributes non-invasive robotic HIFU systems for urology-related and other indications. It also offers Focal One, a HIFU robotic system to treat patients diagnosed with prostate cancer, as...

Industry: Medical Distribution

Sector: Healthcare

Phone: 33 4 72 15 31 50

Website: investor.focalone.com

Address:

Parc dActivites la Poudrette-Lamartine, 4/6, rue du DauphinE, Vaulx-En-Velin, France

Georges8792 Aug. 18 at 10:55 AM

$FOCL we have some insiders who participated in the offering 👍👍👍

0 · Reply

Georges8792 Aug. 18 at 8:17 AM

$FOCL https://www.linkedin.com/posts/clevelandcliniclondon-prostatecancer-focaltherapy-ugcPost-7495164951775584256-uWLs/?utm_source=social_share_send&utm_medium=ios_app&rcm=ACoAADRx6v4B54eq7jmLG3UwhtnBprtqfVsygQg&utm_campaign=share_via

0 · Reply

JBird17 Aug. 17 at 9:15 PM

$FOCL did the offering close? Did they not get the money they wanted?

1 · Reply

MCOPA Aug. 17 at 7:26 PM

$FOCL GARBAGE!!!!!!!!!!!!!!

0 · Reply

Georges8792 Aug. 16 at 8:06 PM

$FOCL https://www.linkedin.com/posts/praanjal-gupta-07a464212_prostatecancer-focaltherapy-focalone-share-7494583058021548032-Bwyg/?utm_source=social_share_send&utm_medium=ios_app&rcm=ACoAADRx6v4B54eq7jmLG3UwhtnBprtqfVsygQg&utm_campaign=share_via

0 · Reply

Georges8792 Aug. 15 at 1:43 AM

$FOCL https://www.linkedin.com/posts/josephmichaelnorris_focaltherapy-imperialprivatecare-prostatecancer-share-7494117315853180928-cNzu/?utm_source=social_share_send&utm_medium=ios_app&rcm=ACoAADRx6v4B54eq7jmLG3UwhtnBprtqfVsygQg&utm_campaign=share_via

0 · Reply

WallStreetWoof Aug. 14 at 2:13 PM

$FOCL Can anyone expand upon the HIFUSSA study ? I am not familiar with this study.

0 · Reply

WallStreetWoof Aug. 14 at 2:13 PM

$FOCL Nice to see 6 analysts covering the call. In the past, it was only 2-3. With the recent issuance of share representing roughly 20% of outstanding shares, we might see short term price targets lower by that percent. Mine was 15 so now $12, but long term very bullish if they can add DIE, histotripsy, and BPH Analysts Mizuho, Anthony Petrone Jason Bednar of Piper Sandler. Michael Sarcone with Jefferies. Sean Lee with H.C. Wainwright. Alex Nowak with Lucid Capital Markets. Josh Jennings with TD Cowen.

0 · Reply

Georges8792 Aug. 14 at 10:59 AM

$FOCL https://www.linkedin.com/posts/joshua-darley-999507115_scotland-cancer-scrubselfie-share-7493920979308482560-wRU4/?utm_source=social_share_send&utm_medium=ios_app&rcm=ACoAADRx6v4B54eq7jmLG3UwhtnBprtqfVsygQg&utm_campaign=share_via

0 · Reply

GKworldtraders Aug. 13 at 9:33 PM

$FOCL Excellent Conference call. Clear and concise. Great potential going forward. Tne extra cash gives them a lot of flexibility to execute the strategy at hand. Well done.👍

0 · Reply

FocalTherics announces American depositary shares offering

2026-08-16T13:27:01.000Z - 3 days ago

FocalTherics price target raised to $4 from $3 at Piper Sandler

Aug 13, 2026, 4:30 PM EDT - 5 days ago

EDAP TMS Earnings Call Transcript: Q2 2026

Aug 13, 2026, 4:30 PM EDT - 5 days ago

EDAP TMS Earnings release: Q2 2026

Aug 13, 2026, 4:30 PM EDT - 5 days ago

EDAP TMS Quarterly report: Q2 2026

Aug 13, 2026, 4:02 PM EDT - 5 days ago

FocalTherics™ Reports Second Quarter 2026 Financial Results

Aug 11, 2026, 9:10 PM EDT - 7 days ago

FocalTherics™ Announces Pricing of Public Offering of American Depositary Shares

Aug 11, 2026, 4:28 PM EDT - 7 days ago

FocalTherics™ Reports Preliminary Financial Results for Second Quarter of 2026

Aug 11, 2026, 4:22 PM EDT - 7 days ago

FocalTherics™ Announces Proposed Public Offering of American Depositary Shares

Jul 30, 2026, 5:00 PM EDT - 19 days ago

FocalTherics™ to Announce Second Quarter 2026 Financial Results on August 13, 2026

2026-07-17T09:50:27.000Z - 4 weeks ago

FocalTherics initiated with an Outperform at Mizuho

Jun 30, 2026, 7:30 AM EDT - 7 weeks ago

FocalTherics™ Announces Successful Launch of First Commercial Endometriosis Focal One® Program in Europe with Treatment of Initial Patients

2026-06-22T10:13:07.000Z - 2 months ago

FocalTherics initiated with a Buy at Lucid Capital

Jun 16, 2026, 7:30 AM EDT - 2 months ago

FocalTherics™ Expands Access to Focal One® Robotic HIFU for Veterans with Prostate Cancer through Agreement with MellingMedical

Jun 4, 2026, 2:00 PM EDT - 2 months ago

EDAP TMS Transcript: Jefferies Global Healthcare Conference 2026

Jun 1, 2026, 8:00 AM EDT - 2 months ago

EDAP TMS Transcript: Investor Day 2026

Jun 1, 2026, 8:00 AM EDT - 2 months ago

EDAP TMS Slides: FY 2026

May 29, 2026, 7:30 AM EDT - 2 months ago

EDAP Announces Corporate Name Change to FocalTherics™ to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy

May 21, 2026, 7:30 AM EDT - 3 months ago

EDAP | Focal One to Present at Jefferies 2026 Global Healthcare Conference

May 14, 2026, 7:30 AM EDT - 3 months ago

EDAP | Focal One and Telix Announce Collaboration Focused on Robotic HIFU and Theranostics in Prostate Cancer

May 13, 2026, 4:30 PM EDT - 3 months ago

EDAP | Focal One to Host Investor Day on June 1, 2026

May 7, 2026, 7:30 AM EDT - 3 months ago

EDAP Reports Strong Financial Results with Record First Quarter HIFU Revenue

Apr 30, 2026, 8:30 AM EDT - 3 months ago

EDAP TMS Strengthens Market Position with Landmark HIFI-2 Data Supporting Focal One® Robotic HIFU in Radiorecurrent Prostate Cancer

Apr 16, 2026, 7:30 AM EDT - 4 months ago

EDAP to Announce First Quarter 2026 Financial Results on May 7, 2026

Mar 25, 2026, 7:30 AM EDT - 5 months ago

EDAP Reports Record Fourth Quarter and Full-Year 2025 HIFU Revenue

Mar 10, 2026, 7:30 AM EDT - 5 months ago

EDAP to Present at Oppenheimer 36th Annual Healthcare MedTech & Services Conference

Mar 4, 2026, 7:30 AM EST - 6 months ago

EDAP to Announce Fourth Quarter and Full Year 2025 Financial Results on March 25, 2026

Feb 12, 2026, 7:30 AM EST - 6 months ago

EDAP Announces Appointment of David Horn to Board of Directors

Jan 12, 2026, 7:30 AM EST - 7 months ago

EDAP Announces Preliminary Record Fourth Quarter and Full Year 2025 HIFU Revenue; Issues 2026 Revenue Guidance

Nov 20, 2025, 7:30 AM EST - 9 months ago

EDAP Receives FDA 510(k) Clearance for Latest Evolution of Focal One Robotic HIFU

Nov 18, 2025, 7:00 AM EST - 9 months ago

EDAP to Present at Piper Sandler 37th Annual Healthcare Conference

Nov 6, 2025, 7:30 AM EST - 10 months ago

EDAP Reports Third Quarter 2025 Financial Results

Nov 4, 2025, 7:00 AM EST - 10 months ago

EDAP to Present at Jefferies Global Healthcare Conference in London

Oct 27, 2025, 7:00 AM EDT - 10 months ago

EDAP to Participate in the UBS Global Healthcare Conference

Oct 23, 2025, 7:00 AM EDT - 10 months ago

EDAP to Announce Third Quarter 2025 Financial Results on November 6, 2025

Oct 20, 2025, 8:30 AM EDT - 10 months ago

EDAP Secures €36 Million Credit Facility from European Investment Bank to Accelerate Growth of Focal One® Robotic HIFU

Sep 30, 2025, 7:00 AM EDT - 11 months ago

Focal One® Prostate Cancer Awareness Month Campaign Shines Spotlight on Robotic HIFU Treatment Option

Sep 16, 2025, 7:00 AM EDT - 1 year ago

Focal One® HIFU Receives Prestigious Innovation Award

Sep 8, 2025, 7:00 AM EDT - 1 year ago

EDAP Receives HIFU Reimbursement for Prostate Cancer in France

Aug 28, 2025, 7:00 AM EDT - 1 year ago

EDAP Reports Strong Second Quarter 2025 HIFU Results

Aug 26, 2025, 7:00 AM EDT - 1 year ago

EDAP Announces Letter of Intent for 36 Million Euro Credit Facility to Accelerate Growth and Strategic Expansion

Aug 25, 2025, 7:00 AM EDT - 1 year ago

EDAP to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 7, 2025, 7:00 AM EDT - 1 year ago

EDAP to Announce Second Quarter 2025 Financial Results on August 28, 2025

Jul 1, 2025, 7:00 AM EDT - 1 year ago

EDAP Announces Transition from Foreign Private Issuer to U.S. Domestic Filer Status

May 27, 2025, 7:00 AM EDT - 1 year ago

EDAP to Present at the Jefferies Global Healthcare Conference

May 15, 2025, 7:00 AM EDT - 1 year ago

EDAP Reports First Quarter 2025 Financial Results

May 1, 2025, 7:00 AM EDT - 1 year ago

EDAP to Announce First Quarter 2025 Financial Results on May 15, 2025

Apr 29, 2025, 7:00 AM EDT - 1 year ago

EDAP Announces Positive Results from the FARP Randomized Controlled Trial Presented at the American Urological Association (AUA) Annual Meeting

Apr 24, 2025, 7:00 AM EDT - 1 year ago

EDAP To Launch New Focal One® i Robotic HIFU system at the Upcoming 120th American Urological Association (AUA) Annual Meeting

Apr 22, 2025, 7:00 AM EDT - 1 year ago

EDAP Announces Significant Presence of Focal One® at the Upcoming 120th American Urological Association (AUA) Annual Meeting

Mar 27, 2025, 8:30 AM EDT - 1 year ago

EDAP TMS Earnings Call Transcript: Q4 2024

Mar 27, 2025, 7:10 AM EDT - 1 year ago

EDAP Reports Record HIFU Fourth Quarter and Full-Year 2024 Results

Mar 6, 2025, 7:00 AM EST - 1 year ago

EDAP to Announce Fourth Quarter and Full Year 2024 Financial Results on March 27, 2025

Mar 3, 2025, 7:00 AM EST - 1 year ago

EDAP Appoints Glen French to Board of Directors

LUNG

Feb 6, 2025, 8:00 AM EST - 1 year ago

Cortechs.ai and EDAP Announce World's First OnQ™ Prostate-Assisted Focal One® Robotic HIFU Procedure at UCSF Prostate Cancer Center

Jan 13, 2025, 7:00 AM EST - 1 year ago

EDAP Announces Preliminary Record Fourth Quarter Focal One® System Sales and Record U.S. Procedures

Jan 10, 2025, 7:00 AM EST - 1 year ago

EDAP Appoints Joshua H. Levine to Board of Directors

Jan 8, 2025, 7:00 AM EST - 1 year ago

EDAP Announces First Pancreatic Cancer Patient Treated with Proprietary HIFU Technology

Dec 4, 2024, 9:10 AM EST - 1 year ago

Landmark HIFI Study Publication Demonstrates Positive Outcomes with Focal One® Robotic HIFU Versus Surgery in the Management of Prostate Cancer

Nov 19, 2024, 8:00 AM EST - 1 year ago

EDAP Announces Scientific Presentation at 2024 AAGL Global Congress Comparing Focal One HIFU Versus Surgery for the Treatment of Deep Infiltrating Endometriosis

Oct 24, 2024, 8:00 AM EDT - 1 year ago

EDAP to Announce Third Quarter 2024 Financial Results on November 7, 2024

Georges8792 Aug. 18 at 10:55 AM

$FOCL we have some insiders who participated in the offering 👍👍👍

0 · Reply

Georges8792 Aug. 18 at 8:17 AM

0 · Reply

JBird17 Aug. 17 at 9:15 PM

$FOCL did the offering close? Did they not get the money they wanted?

1 · Reply

MCOPA Aug. 17 at 7:26 PM

$FOCL GARBAGE!!!!!!!!!!!!!!

0 · Reply

Georges8792 Aug. 16 at 8:06 PM

0 · Reply

Georges8792 Aug. 15 at 1:43 AM

0 · Reply

WallStreetWoof Aug. 14 at 2:13 PM

$FOCL Can anyone expand upon the HIFUSSA study ? I am not familiar with this study.

0 · Reply

WallStreetWoof Aug. 14 at 2:13 PM

0 · Reply

Georges8792 Aug. 14 at 10:59 AM

0 · Reply

GKworldtraders Aug. 13 at 9:33 PM

$FOCL Excellent Conference call. Clear and concise. Great potential going forward. Tne extra cash gives them a lot of flexibility to execute the strategy at hand. Well done.👍

0 · Reply

WallStreetWoof Aug. 13 at 8:35 PM

$FOCL Two things caught my attention: 1)"...integrating histotripsy together with HIFU on our Focal One platform". Histotripsy is a noninvasive, FDA-approved procedure that uses focused ultrasound to destroy liver tumors by creating tiny bubbles in cancerous tissue. It is an alternative for patients who cannot have surgery. 2)..."The increase in net loss was primarily attributable to the European Investment Bank warrant valuation impact of $5.5 million during the quarter." The loss was 8.0M, so subtract 5.5M and you have a 2.5M loss from ops...which is significantly better than the 6.6M loss in Q2 2025 (ie last year).

0 · Reply

MCOPA Aug. 13 at 8:31 PM

$FOCL GREAT QUARTER GUYS!!! Like a broken record every conference call!

0 · Reply

mikegrand Aug. 13 at 8:30 PM

$FOCL other than the high cash burn (which they said was related to the US filing and the loan interest payment) they seem to be in line with all previously mentioned benchmarks during the investor conference The cash burn definitely explains why they wanted to get the offering done quickly. All in all pretty standard Q, glad to see another quarter of double digit usage increase (the machine selling doesn’t make the money, it’s the usage that does)

1 · Reply

WallStreetWoof Aug. 13 at 3:44 PM

$FOCL Well I bought my written calls back at 0.55. Seems FOCL mgmt decided to flip the script this quarterly report, a dump n pump rather than a pump n dump. Nice to see more posts on the board

0 · Reply

Georges8792 Aug. 13 at 3:24 PM

$FOCL https://www.linkedin.com/posts/rajesh-k-ahlawat-b368319b_prostatecancer-focaltherapy-hifu-share-7493470619468988416-oekj/?utm_source=social_share_send&utm_medium=ios_app&rcm=ACoAADRx6v4B54eq7jmLG3UwhtnBprtqfVsygQg&utm_campaign=share_via

0 · Reply

MCOPA Aug. 12 at 5:20 PM

$FOCL LIKE I SAID BEFORE IT TAKES A MONTH TO GO UP AND 1 DAY TO DROP IT ALL!

0 · Reply

Sonnab10 Aug. 12 at 5:01 PM

$FOCL EDAP should have changed its stock symbol to SKATA!

2 · Reply

mikegrand Aug. 12 at 2:42 PM

$FOCL in all reality, this is a dilution caused by outside need for money but doesn’t reflect on progression of company overall. In this case, if you have the money available, this can be seen as a time to build a larger position. I put another $10K in to counter the dilution. I expect Q2 on Thursday will at least bounce us back to the mid $5 (especially if the estimates hit on the high end)

0 · Reply

mikegrand Aug. 12 at 1:40 PM

$FOCL so it’s a rough day but we all saw a dilution coming sooner or later (don’t like it but knew it was gonna happen as the cash burn was exceeding the loan). The good news is it’s over and they do have enough money to last until their estimated positive EBIDTA timeline. Hopefully it will be a little bit of excess if endometriosis takes off faster than expected Ultimately when it comes to Q2 they are hitting their estimates from the investors conference so just as long as they remain this route (or improve upon it), everything is pretty expected.

2 · Reply

OpenOutcrier Aug. 12 at 12:57 PM

$FOCL (-23.5% pre) FocalTherics prices public offering of 8.4 million ADS at $4.75 each https://ooc.bz/l/110989

0 · Reply

JBird17 Aug. 12 at 12:35 PM

$FOCL anytime this thing gets legs, management cuts them off and lets it slide back down the hill.

1 · Reply

briefingcom Aug. 12 at 12:01 PM

$FOCL: FocalTherics (-19.1%) prices offering of 8.425 mln ADSs at $4.75 per ADS.

0 · Reply

Market Cap	163.42M
Revenue (ttm)	70.53M
Net Income (ttm)	-29.25M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-41.47%
Debt to Equity Ratio	2.41

Volume	339,900
Avg Vol	102,252
Day's Range	N/A - N/A
Shares Out	37.48M
Stochastic %K	8%
Beta	-0.04
Analysts	Sell
Price Target	$8.38